Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Among 16 human immunodeficiency virus-infected (subtype C) Batswana patients who failed nelfinavir (NFV)-containing regimens, the most prevalent mutation observed was D30N (54%), followed by L90M (31%). L89I, K20T/I, and E35D polymorphic changes were also identified. These findings suggest that subtype C viruses in Botswana may develop resistance to NFV via subtype-specific pathways.
Doualla-Bell
Florence
F
Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Gaborone.
Avalos
Ava
A
Gaolathe
Tendani
T
Mine
Madisa
M
Gaseitsiwe
Simani
S
Ndwapi
Ndwapi
N
Novitsky
Vladimir A
VA
Brenner
Bluma
B
Oliveira
Maureen
M
Moisi
Daniella
D
Moffat
Howard
H
Thior
Ibou
I
Essex
Max
M
Wainberg
Mark A
MA
D019943:Amino Acid Substitution; D018791:CD4 Lymphocyte Count; D024882:Drug Resistance, Viral / Q000235:genetics*; D014644:Genetic Variation; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000145:classification / Q000187:drug effects* / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D009154:Mutation; D019888:Nelfinavir / Q000494:pharmacology* / Q000627:therapeutic use; D010802:Phylogeny; D011110:Polymorphism, Genetic; D015995:Prevalence; D012367:RNA, Viral / Q000737:chemistry / Q000235:genetics; D012641:Selection, Genetic; D017211:Treatment Failure; D019562:Viral Load; D014779:Virus Replication / Q000187:drug effects
D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D019888:Nelfinavir